Research at Oslo University Hospital basis for international drug development initiative between Norway and India
SERCA Pharmaceuticals AS, a company established by Inven2 AS in October, recently entered a co-development agreement with Cadila Pharmaceuticals - an FDA-approved Indian Pharma company with some 6000 employees. SERCA Pharmaceuticals AS is established based on a drug development and innovation project on ischemia reperfusion injury in myocardial infarction that has been going on in the groups of Professors Kjetil Tasken (formerly NCMM UiO/OUH, now ICR, OUH) and Ivar Sjaastad (IEMF, OUH). The researchers have taken this forward to a drug candidate and have documented effects biochemically, in heart cells, by electrophysiology, on normal rat hearts and in rats with ischemia reperfusion injury where there is a cardioprotective effect.
The work has involved Birgitte Lygren (former postdoc), Ellen Østensen (PhD 2016), Ana Calejo (former postdoc and now researcher with UiO SPARK grant) in the Taskén group at UiO/OUH and has been done in collaboration with Professor Jo Klaveness at Institute of Pharmacy and Professor Ivar Sjaastad and Researcher Jan Magnus Aaronsen at Institute of Experimental Medical Research at Oslo University Hospital and in collaboration with Inven2, particularly Mohammed Amarzguioui and Kristin Sandereid, that have been involved in the technology and business development and led to the establishment of SERCA Pharmaceuticals AS.
SERCA Pharmaceuticals AS has won a 5-mill NOK Forny grant from RCN. The agreement with Cadila will take the project forward and provides a real chance to go into humans with planned phase 1 and 2 studies.
Inven2's most recent startup company, Serca Pharmaceuticals, signed a development agreement with Cadila Pharmaceuticals in New Delhi today. The signing was overseen by Prime Minister of Norway, Erna Solberg, during her official visit to India. Serca Pharmaceuticals is based on breakthrough science from Kjetil Taskéns Group at the University of Oslo. Read more
Published in Level 2 journals, first or last author from Oslo University Hospital.
Gjølberg TT, Wik JA, Johannessen H, Krüger S, Bassi N, Christopoulos PF, Bern M, Foss S, Petrovski G, Moe MC, Haraldsen G, Fosse JH, Skålhegg BS, Andersen JT, Sundlisæter E(2023) Antibody blockade of Jagged1 attenuates choroidal neovascularization Nat Commun, 14(1), 3109 DOI 10.1038/s41467-023-38563-w, PubMed 37253747
Skaane P(2023) Interval and Successive-Round Cancers after Digital Breast Tomosynthesis Screening: We Still Need Convincing Results regarding Beneficial Evidence on Long-term Outcomes Radiology, 307(5), e230964 DOI 10.1148/radiol.230964, PubMed 37249434
Tunold JA, Tan MMX, Koga S, Geut H, Rozemuller AJM, Valentino R, Sekiya H, Martin NB, Heckman MG, Bras J, Guerreiro R, Dickson DW, Toft M, van de Berg W, Ross OA, Pihlstrøm L(2023) Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease Brain(in press) DOI 10.1093/brain/awad183, PubMed 37247383